Holen Sie sich die Stockscreener-App
1.69
0.59%
-0.01
Neuroone Medical Technologies Corp Aktie (NMTC) Neueste Nachrichten
NeuroOne(R) Highlights Potential Paradigm Shift for Patients Treated With the OneRF(R) Brain Ablation System Based on Reports by Physicians - Yahoo Finance
NeuroOne Medical Technologies Corp (NMTC) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NeuroOne Medical Technologies Corp (NMTC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NeuroOne Medical Technologies Corp (NMTC) Cash Flow - TradingKey
NeuroOne Medical Technologies Corp (NMTC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NMTC|NeuroOne Medical Technologies Corp|Price:1.900|Chg%:+0.050 - TradingKey
NeuroOne(R) Expands Drug Delivery Program Through Collaboration on Pediatric Brain Cancer Clinical Trial - Yahoo Finance
Brian and Barbara Pratt disclose 12.5% NeuroOne stake (NASDAQ: NMTC) - Stock Titan
NeuroOne Medical Technologies (NMTC) Brian Pratt reports 1,085,934 shares - Stock Titan
Insider Sell: Mark Christianson Sells 10,000 Shares of NeuroOne Medical Technologies Corp (NMTC) - GuruFocus
NMTC (NMTC) director sells 10,000 shares, retains 20,692 after trade - Stock Titan
NeuroOne Medical Technologies Corp. Hits New 52-Week Low at $2.93 - MarketsMojo
Form 144 NEUROONE MEDICAL TECHNOLOGIES Corp For: 30 June - Investing.com UK
NeuroOne Medical Technologies (NMTC) Weighs on Support After 4.58% DeclineSign of Strength - dars.gov.et
Form 144 NEUROONE MEDICAL TECHNOLOGIES Corp For: 30 June By Investing.com - Investing.com South Africa
[144] NEUROONE MEDICAL TECHNOLOGIES Corp SEC Filing - Stock Titan
NeuroOne(R) Added to Russell Microcap(R) Index - Yahoo Finance
Form DEF 14A Neuroone Medical Technologies Corp For: 26 June By Investing.com - Investing.com South Africa
NeuroOne(R) Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
NMTC Should I Buy - Intellectia AI
NeuroOne Medical Technologies Corp. Hits 52-Week Low at $3.16 Amid Challenges - MarketsMojo
NeuroOne Medical Technologies Corp (NMTC) Institutional Confidence - TradingKey
NeuroOne Medical Technologies Corp (NMTC) Valuation: PE, PB & Fair Value Analysis - TradingKey
NeuroOne Medical Technologies Corp (NMTC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NeuroOne Medical Technologies Corp (NMTC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NeuroOne Medical Technologies Corp (NMTC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
NeuroOne Medical Technologies Corp - TradingKey
NeuroOne(R) Announces Preliminary Inclusion in Russell Microcap(R) Index - Yahoo Finance
NeuroOne Medical Technologies 10-Q/A Restatement for Q2 2026 – Financial Statement Corrections and Impact - Minichart
NeuroOne Medical Technologies Corporation Files Form 8-K Current Report with NASDAQ Listing Information - Minichart
NeuroOne Medical Technologies updates at-the-market offering for up to $13.4 million - Investing.com
NeuroOne to sell up to $13.4M in common stock through updated ATM prospectus - TradingView
NeuroOne (NASDAQ: NMTC) ups at‑the‑market capacity to $13.4M via JonesTrading - Stock Titan
NeuroOne Medical Technologies (NMTC) refreshes $13.4M at-the-market share offering - Stock Titan
NeuroOne Medical (NASDAQ: NMTC) restates revenue and warns on going concern - Stock Titan
NeuroOne(R) to Present at the Planet MicroCap Las Vegas 2026 Conference Wednesday, June 17, 2026 at 12:00 p.m. Pacific Time - Yahoo Finance
NMTC Q1 2026 Earnings: EPS Misses Estimates as Development-Stage Costs PersistGeographic Revenue Trends - newsline.com
NeuroOne (NMTC) Q2 2026 Earnings Transcript - AOL.com
NMTCNeuroOne Medical Technologies Corp Stock Price and Quote - Finviz
NeuroOne(R) to Present at the 2026 American Society for Stereotactic and Functional Neurosurgery Biennial Meeting on May 31, 2026 - Yahoo Finance
NeuroOne Medical | 4: Statement of changes in beneficial ownership of securities-Officer Christianson Mark - Moomoo
NeuroOne Medical Technologies to Restate Q1 2026 Financials After Revenue Overstatement; Reaffirms $10.5M FY2026 Guidance - Minichart
According to documents submitted by NEUROONE MEDICAL TECH to the U.S. Securities and Exchange Commission, the company has restated its financial data for the first quarter of 2026 to correct a previous overstatement of revenue by approximately $50 - Bitget
NeuroOne(R) Medical Technologies Announces Restatement of Financial Results for Quarter Ending March 31, 2026 - Scott Coop
NeuroOne (Nasdaq: NMTC) to restate March 31 2026 results, keeps guidance - Stock Titan
Earnings call transcript: NeuroOne misses Q2 2026 forecasts, stock rises By Investing.com - Investing.com South Africa
Earnings call transcript: NeuroOne misses Q2 2026 forecasts, stock rises - Investing.com
Minne InnoNeuroOne CEO Dave Rosa talks uplisting on Nasdaq, year ahead - The Business Journals
Maxim Group Maintains NeuroOne Medical(NMTC.US) With Buy Rating, Maintains Target Price $13 - Moomoo
NMTC Maintains Buy Rating by Ladenburg Thalmann -- Price Target Raised to $8.80 - GuruFocus
NeuroOne Medical Tech Price Target Raised to $8.00/Share From $1.60 by Ladenburg Thalmann - Moomoo
NeuroOne Medical Tech Q2 2026 Earnings Call Transcript - Sahm
NeuroOne Medical (NMTC) Price Target Raised to $8 - GuruFocus
Ladenburg Thalmann Maintains NeuroOne Medical(NMTC.US) With Buy Rating, Cuts Target Price to $8 - Moomoo
NeuroOne Medical Technologies Corporation Q2 2026 Earnings Call Summary - Yahoo Finance
1.04%
11.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):